Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

KRAS and BRAF: drug targets and predictive biomarkers.

Vakiani E, Solit DB.

J Pathol. 2011 Jan;223(2):219-29. doi: 10.1002/path.2796. Epub 2010 Oct 28. Review.

PMID:
21125676
2.

Phosphatidylinositol-4,5-bisphosphate regulates epidermal growth factor receptor activation.

Michailidis IE, Rusinova R, Georgakopoulos A, Chen Y, Iyengar R, Robakis NK, Logothetis DE, Baki L.

Pflugers Arch. 2011 Mar;461(3):387-97. doi: 10.1007/s00424-010-0904-3. Epub 2010 Nov 24.

3.

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.

JAMA. 2010 Oct 27;304(16):1812-20. doi: 10.1001/jama.2010.1535.

PMID:
20978259
4.

Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Wheeler DL, Dunn EF, Harari PM.

Nat Rev Clin Oncol. 2010 Sep;7(9):493-507. doi: 10.1038/nrclinonc.2010.97. Epub 2010 Jun 15. Review.

5.

Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.

Pines G, Köstler WJ, Yarden Y.

FEBS Lett. 2010 Jun 18;584(12):2699-706. doi: 10.1016/j.febslet.2010.04.019. Epub 2010 Apr 11. Review.

6.

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.

Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, Fulgham A, Song Y, Nielsen UB, Engelman JA, Wong KK.

Cancer Res. 2010 Mar 15;70(6):2485-94. doi: 10.1158/0008-5472.CAN-09-3145. Epub 2010 Mar 9.

7.

EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.

Takeuchi K, Ito F.

FEBS J. 2010 Jan;277(2):316-26. doi: 10.1111/j.1742-4658.2009.07450.x. Epub 2009 Nov 18. Review.

8.

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.

Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J.

Cell. 2009 Jun 26;137(7):1293-307. doi: 10.1016/j.cell.2009.04.025. Erratum in: Cell. 2009 Aug 7;138(3):604.

9.

The juxtamembrane region of the EGF receptor functions as an activation domain.

Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G.

Mol Cell. 2009 Jun 26;34(6):641-51. doi: 10.1016/j.molcel.2009.04.034.

10.

The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding.

Macdonald-Obermann JL, Pike LJ.

J Biol Chem. 2009 May 15;284(20):13570-6. doi: 10.1074/jbc.M109.001487. Epub 2009 Mar 31.

11.

p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047.

Adachi S, Natsume H, Yamauchi J, Matsushima-Nishiwaki R, Joe AK, Moriwaki H, Kozawa O.

Cancer Lett. 2009 May 8;277(1):108-13. doi: 10.1016/j.canlet.2008.11.034. Epub 2009 Jan 12.

PMID:
19138820
12.

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S.

Lancet Oncol. 2008 Oct;9(10):962-72. doi: 10.1016/S1470-2045(08)70206-7. Epub 2008 Sep 17. Review.

PMID:
18804418
13.

EGFR family: structure physiology signalling and therapeutic targets.

Burgess AW.

Growth Factors. 2008 Oct;26(5):263-74. doi: 10.1080/08977190802312844. Review.

PMID:
18800267
14.

Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation.

Thiel KW, Carpenter G.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19238-43. Epub 2007 Nov 27.

15.

Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis.

Garbe JC, Holst CR, Bassett E, Tlsty T, Stampfer MR.

Cell Cycle. 2007 Aug 1;6(15):1927-36. Epub 2007 May 30.

PMID:
17671422
16.

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.

PMID:
17635524
17.

Targeting the EGFR pathway for cancer therapy.

Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M.

Curr Med Chem. 2006;13(29):3483-92. Review.

PMID:
17168718
18.

Structure of the membrane reconstituted transmembrane-juxtamembrane peptide EGFR(622-660) and its interaction with Ca2+/calmodulin.

Sato T, Pallavi P, Golebiewska U, McLaughlin S, Smith SO.

Biochemistry. 2006 Oct 24;45(42):12704-14.

PMID:
17042488
19.
20.

Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

Schaefer KL, Brachwitz K, Braun Y, Diallo R, Wai DH, Zahn S, Schneider DT, Kuhnen C, Vollmann A, Brockhoff G, Gabbert HE, Poremba C.

Neoplasia. 2006 Jul;8(7):613-22.

Supplemental Content

Support Center